The proliferation of M-07e cells treated with increasing concentrations of mSCF was assessed. After 48 hour treatment with mSCF, cells were incubated with a tetrazolium salt and the OD450 - OD650 was determined.
The purity of recombinant mSCF was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant mSCF and staining overnight with Coomassie Blue.
Western blot analysis of extracts from M-07e cells untreated or treated with mSCF for 5 minutes, using Phospho-c-Kit (Tyr719) Antibody #3391 (upper) and c-Kit (D13A2) XP® Rabbit mAb #3074 (lower).
With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg mSCF. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.
Stable in lyophilized state at 4°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles.Maintain sterility. Storage at -20°C should be in a manual defrost freezer.
>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant mSCF. All lots are greater than 98% pure.
Recombinant mSCF contains no "tags" and the nonglycosylated protein has a calculated MW of 18,298. DTT-reduced and non-reduced protein migrate as 22-35 kDa polypeptides. Lower mobility and heterogeneity in SDS-PAGE are due to glycosylation. The expected amino-terminal KEICG of recombinant mSCF was verified by amino acid sequencing.
The bioactivity of recombinant mSCF was determined in an M-07e cell proliferation assay. The ED50 of each lot is between 2-8 ng/ml.
Less than 0.01 ng endotoxin/1 μg mSCF.
Recombinant mouse SCF (mSCF) Lys26-Ala189 (Accession #NP_038626) was expressed in human 293 cells at Cell Signaling Technology.
SCF is produced by endothelial cells, fibroblasts, keratinocytes, gut epithelial cells, and tumor cells (1,2). SCF is critical for hematopoiesis and mast cell differentiation and has additional roles in survival and function of other cell types (1). Some tumor cell proliferation and invasiveness are promoted by SCF (3). Tumor-derived SCF appears to be involved in expansion of myeloid-derived suppressor cells which, in turn, limits proliferation of tumor-infiltrating T-cells (4). SCF may have additional roles in the tumor microenvironment (2). SCF is either soluble or an integral membrane protein and its form is dependant on variation in splicing or proteolytic release (1). SCF binds to the receptor tyrosine kinase c-Kit and induces activation of the Akt, Erk, JNK, and p38 pathways (5,6).
Explore pathways + proteins related to this product.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.